๐ŸŽ Black Friday: 50% off Unlimited and 30% off Pro annual plans
HLS Therapeutics Inc. (TSX:HLS)
Canada flag Canada ยท Delayed Price ยท Currency is CAD
3.650
-0.020 (-0.54%)
Nov 20, 2026, 4:00 PM EST

HLS Therapeutics Earnings Call Transcripts

Fiscal Year 2026

  • Q3 revenue rose 5% YoY, while cardiovascular sales grew ~21% in local currency and NILEMDO continued to ramp. 2026 Adjusted EBITDA is expected in the lower half of guidance as launch spending and product mix weigh; growth is expected to step up in 2027.

  • Product-led growth and debt reduction strengthened cash generation, while 2026 cardiovascular launches and payer milestones set up a potential growth inflection in 2027. The strategy includes disciplined in-licensing and shareholder returns.

  • Cardiovascular net sales surged 25% year-over-year, driven by Vascepa and a robust NILEMDO launch, while CLOZARIL's Canadian patient base grew for five months. Cash flow and balance sheet strength enabled share buybacks and ongoing debt reduction. 2026 guidance is reaffirmed.

  • AGM 2026

    The meeting addressed financial statements, elected Directors, reappointed the Auditor, and approved the Long-Term Incentive Plan, with all resolutions passing. Voting was conducted virtually, and results will be disclosed on SEDAR+ and via press release.

  • Q1 2026 saw 2% revenue growth, strong Vascepa sales, and a successful NILEMDO launch with rapid private payer coverage. Operational improvements boosted cash flow and reduced net debt, while guidance for 2026 was reaffirmed and margin expansion is expected in the second half.

  • Operational improvements and a strengthened balance sheet have set the stage for accelerated growth, with new cardiovascular launches like Nilemdo and NEXLIZET targeting significant unmet needs. Early market access wins and a robust product pipeline support a positive outlook through 2027.

Fiscal Year 2025

Fiscal Year 2024

Fiscal Year 2023

Fiscal Year 2022